Increase of XXXX dose deteriorates mood during progestin phase in sequential hormonal therapy.

@entity1 @entity172 @entity11796 @entity146 @entity53 @entity1871 @entity2701 @entity3010
Previous studies have indicated that the addition of progestins during sequential hormonal replacement therapy (HRT) causes negative mood and physical symptoms. History of @entity3010 , type of progestin, and dose of @entity1871 have thus far been shown to influence the progestin-induced adverse mood symptoms during HRT. The aim of this study was to compare adverse mood effects of two different doses of @entity53 , in combination with a progestin, during postmenopausal HRT. Twenty-eight perimenopausal @entity1 were included in this randomized, double-blind, crossover study comparing 2- or 3-mg continuous @entity53 , with an addition of 10 mg @entity11796 on d 17-28 during each treatment cycle. The main outcome measures were mood and physical symptoms kept on a daily rating scale. Together with the progestin, the higher dose of @entity172 caused significantly more negative mood symptoms than the lower dose. @entity2701 , @entity146 , and depressed mood were all significantly augmented during the progestin phase of cycles with 3 mg @entity53 (P < 0.001). Physical symptoms also increased during the progestin phase of 3-mg @entity53 cycles (P < 0.001), whereas positive mood symptoms were less affected. The only positive mood that changed with @entity172 dose was friendliness, which decreased during the progestin phase of high @entity53 cycles compared with cycles with lower @entity53 (P < 0.05). Our conclusion is that an increase of the @entity172 dose accentuates negative mood and physical symptoms during the progestin phase of sequential hormonal therapy.
